Cardiol Therapeutics Inc represents a strong commitment to improving cardiovascular health through innovative therapies. With a core philosophy centered around scientific excellence and patient-centric approach, Cardiol aims to develop safe and effective cannabidiol-based pharmaceuticals. The company focuses on rigorous research and development, clinical trials, and strategic partnerships to deliver breakthrough treatments for heart diseases. By prioritizing the well-being of patients, Cardiol Therapeutics Inc strives to redefine cardiovascular care and contribute to healthier lives.

Cardiol Therapeutics Inc is primarily present in various countries and regions around the world. The company has a global reach and engages in its operations in multiple places. With its headquarters in Canada, Cardiol Therapeutics Inc has a strong presence in North America, particularly in the United States. Additionally, the company has established partnerships and collaborations globally, allowing it to extend its reach to other regions and countries. Cardiol Therapeutics Inc's commitment to expanding its market presence ensures its innovative healthcare solutions reach patients and healthcare professionals worldwide.

Cardiol Therapeutics Inc has achieved several significant milestones. The company successfully completed its Phase 2 clinical trial evaluating CardiolRx™ for the treatment of acute myocarditis, a severe inflammatory condition of the heart. Additionally, Cardiol Therapeutics Inc received a patent grant from the United States Patent and Trademark Office for its unique methods in treating various forms of heart failure using cannabinoids. The company also obtained a license agreement with Dalton Pharma Services, a leading contract development and manufacturing organization, to support the production of pharmaceutical-grade cannabidiol. These milestones demonstrate Cardiol Therapeutics Inc's dedication to advancing innovative therapies and solidify its position in the pharmaceutical industry.

Cardiol Therapeutics Inc. is a pharmaceutical company specializing in the development and commercialization of cutting-edge therapies for cardiovascular diseases. Founded in 2013, Cardiol Therapeutics has quickly emerged as a leader in the field, with a strong focus on cannabinoid-based treatments. The company's innovative research and development efforts have resulted in the development of CardiolRx™, a proprietary pharmaceutical cannabidiol formulation that targets heart diseases. With a relentless dedication to improving patient outcomes, Cardiol Therapeutics is committed to bringing forth effective and safe medicinal solutions for various cardiovascular conditions. They continuously collaborate with leading researchers and medical professionals to advance their mission of revolutionizing cardiovascular care.

The main competitors of Cardiol Therapeutics Inc in the market include companies like GW Pharmaceuticals, Amarin Corporation, Novartis Pharmaceuticals, and Pfizer Inc.

Cardiol Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.

The business model of Cardiol Therapeutics Inc revolves around the development and commercialization of pharmaceutical products. The company focuses on producing innovative therapies for various medical conditions, particularly those related to heart diseases. Cardiol Therapeutics Inc aims to leverage advanced scientific research and technologies to create effective treatments for cardiovascular disorders. With a strong commitment to improving patients' lives, the company actively engages in clinical trials and collaborations with experts in the field. Cardiol Therapeutics Inc strives to provide solutions that address significant unmet medical needs, positioning itself as a leader in the cardiovascular health industry.

Cardiol Therapeutics P/E suhe on −5,73.

Cardiol Therapeutics KUV on 0.

AlleAktien kvaliteediskoor ettevõttele Cardiol Therapeutics on 2/10.

Praegu ei saa Cardiol Therapeutics käivet arvutada.

oodatud Cardiol Therapeutics kasum on −30,17 mln. CAD.

Cardiol Therapeutics Inc is a Canadian biopharmaceutical company specializing in the development of innovative therapies for the treatment of cardiovascular diseases. The company is headquartered in Oakville, Ontario and is listed on the Toronto Stock Exchange and the NASDAQ. Cardiol Therapeutics' business model is based on the research, development, and commercialization of novel treatments for cardiovascular system diseases, including chronic heart failure, coronary artery disease, and heart attack. The company focuses on the application of cannabinoids as the basis for its therapeutics. Cardiol Therapeutics' flagship product is the drug candidate CardiolRx, a synthetic cannabidiol (CBD) derivative. It is intended to improve endogenous repair mechanisms after a heart attack. The company has successfully completed the clinical development of CardiolRx; the Phase 3 study (TIMI 3 study) has demonstrated the effectiveness and safety of the drug candidate in patients with heart attack. The approval of CardiolRx is currently being sought from regulatory authorities in the United States and Europe. CardiolRx is being conducted by Cardiol Therapeutics itself. However, CardiolRx is not the only product that Cardiol Therapeutics has in its pipeline. The company has a portfolio of drug candidates that include both synthetic cannabinoids and natural products. Currently, the company is developing another cannabinoid-based medication, CardiolRx + CBD. This product is a combination of the already approved CardiolRx and natural CBD. CardiolRx + CBD is currently undergoing clinical trials. In addition to its pharmaceutical products, Cardiol Therapeutics also operates a research program focused on studying the therapeutic effects of cannabinoids on the cardiovascular system. The company aims to understand the mechanisms of action of cannabinoids on the heart and develop further medical applications. In addition to its research and development work, Cardiol Therapeutics has also entered into partnerships with other companies. In 2019, the company signed an agreement with Apic Bio to jointly develop gene therapy for the treatment of heart failure. Under this agreement, Apic Bio will assist in preparing an Investigational New Drug (IND) submission to the FDA. Cardiol Therapeutics' business model is based on an innovative research platform and a broad pipeline of drug candidates that utilize the therapeutic effects of cannabinoids on the cardiovascular system. The company aims to solidify its leading position in this field and market its products globally. With its experienced management team and strong research results, Cardiol Therapeutics is expected to continue to be successful and have the potential to save lives and improve the health of millions of people worldwide. The main focus of Cardiol Therapeutics is the development of innovative therapies for cardiovascular diseases using cannabinoids. They have successfully completed the clinical development of CardiolRx and are seeking approval for its use in treating heart attack patients. They are also developing other cannabinoid-based medications, such as CardiolRx + CBD. The company also conducts research on the therapeutic effects of cannabinoids on the cardiovascular system. They have partnerships with other companies, such as Apic Bio, to develop gene therapy for heart failure. The company aims to solidify its position in the market and globally market its products.

Cardiol Therapeutics maksab dividendi 0 CAD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Cardiol Therapeutics jaoks arvutada või ettevõte ei maksa dividende välja.

Cardiol Therapeutics ISIN on CA14161Y2006.

Cardiol Therapeutics WKN on A2PA9E.

Cardiol Therapeutics tähis on CRDL.TO.

Viimase 12 kuu jooksul maksis Cardiol Therapeutics dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Cardiol Therapeutics tõenäoliselt dividendi summas 0 CAD.

Cardiol Therapeutics praegune dividenditootlus on .

Cardiol Therapeutics maksab kvartaalset dividendi. See makstakse välja kuudel .

Cardiol Therapeutics maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 CAD. See vastab dividenditootlusele 0 %.

Cardiol Therapeutics on liigitatud sektorisse 'Tervis'.

Viimase Cardiol Therapeutics dividendide saamiseks 2.10.2024 suuruses 0 CAD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 2.10.2024.

Viimane dividendimakse toimus 2.10.2024.

Aastal 2023 maksis Cardiol Therapeutics 0 CAD dividende.

Cardiol Therapeutics dividendid makstakse välja CAD.